To include your compound in the COVID-19 Resource Center, submit it here.

Playing tax arbitrage

Valeant's tax structure would boost to earnings from takeover target Cephalon

Cephalon Inc. rejected Valeant Pharmaceuticals International Inc.'s hostile bid last week as too low, but the advantages Valeant's tax structure provides make it hard to see how Cephalon can compete for the affections of shareholders. Thus the response may just be a tactical move to nudge up the offer of $5.7 billion, or $73 per share in cash.

Valeant anticipates a tax rate of about 8% in 4Q10 and has estimated a tax rate of around 10% for 2011. In contrast, Cephalon expects its 2010 tax rate will be about 33%.

Last year, Cephalon had $618.8 million in income before taxes. It accounted for $201.1 million in income tax expense, leaving it with net income of

Read the full 1147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers